-
effectivehealthcare.ahrq.gov/sites/default/files/01_-arthritis_potential_high_impact_june_2012.pdf
January 01, 2012 - observed in clinical trials completed to date, such as infections, increases in cholesterol levels, and
liver
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/high-cholestorol-medications_disposition-comments.pdf
March 10, 2010 - potency could potentially increase
frequency of important adverse events such as rhabdomyolysis and liver
-
effectivehealthcare.ahrq.gov/sites/default/files/product/pdf/research-gap-primary-care-summary-table.pdf
March 01, 2022 - NSAIDs have increased
risk of serious gastrointestinal, liver dysfunction,
and cardiovascular adverse
-
effectivehealthcare.ahrq.gov/sites/default/files/01_arthritis_potential_high_impact_2012-12-10.pdf
January 01, 2012 - observed in clinical trials completed to date, such as infections,
increases in cholesterol levels, and liver
-
effectivehealthcare.ahrq.gov/sites/default/files/obesity_hi_impact.pdf
April 17, 2012 - relaying new safety information to health care professionals and patients about rare
cases of severe liver
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/surveillance-report-2-nonopioid-pharm-chronic-pain.pdf
April 01, 2022 - Specific adverse events for each drug class, such as
gastrointestinal events, cardiovascular events, and liver
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/weight-loss-surgery_disposition-comments.pdf
June 05, 2013 - I would consider fatty liver disease,
metabolic syndrome, etc. conditions that would fall under
'metabolic
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/hepatitis-c-treatment-adherence_disposition-comments.pdf
December 20, 2012 - clinically relevant, and highlight the need for research in final
health outcomes, particularly clinical liver
-
effectivehealthcare.ahrq.gov/sites/default/files/pulmonary-horizon-scan-high-impact-1312.pdf
December 01, 2013 - this caveat about the demand for donor lungs: “[It] is much
lower than the demand for kidneys and livers
-
effectivehealthcare.ahrq.gov/sites/default/files/ch_6-user-guide-to-ocer_130129.pdf
October 30, 2012 - or more aggressive
in those with one treatment than another (i.e.,
surveillance bias, e.g., when liver
-
effectivehealthcare.ahrq.gov/health-topics/period-pain
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/cystic-fibrosis-hgh_executive.pdf
October 01, 2010 - CF patients on rhGH rarely experienced a
transient increase in liver transaminases in two single-
arm
-
effectivehealthcare.ahrq.gov/sites/default/files/08_functional_limitations_potential_high_impact_2012-12-10.pdf
January 01, 2012 - lymphocyte counts, diarrhea, flushing, gastrointestinal
symptoms, headache, and a mild increase in liver … events associated with dimethyl fumarate included “diarrhea, decreased lymphocyte
counts, elevated liver
-
effectivehealthcare.ahrq.gov/sites/default/files/tech-brief-37-opiod-use-adults-comments.pdf
November 03, 2020 - /opioids-older-adults/report
Published Online: November 3, 2020
81
cause further damage to my liver … after having a negative reaction
to synthetic chemicals of other pain medications,
without harming my liver
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/meditation_executive.pdf
January 01, 2014 - trial specified
that the researchers looked for toxicities of meditation to
hematologic, renal, and liver
-
effectivehealthcare.ahrq.gov/sites/default/files/obesity-horizon-scan-high-impact-1506.pdf
June 01, 2015 - hyperglycemia and blocks the effects of glucagon, a
hormone produced in the pancreas that signals the liver
-
effectivehealthcare.ahrq.gov/sites/default/files/07_diabetes_potential_high_impact_june_2012.pdf
January 01, 2012 - consistently maintained, using an insulin-only system or a bi-hormonal system that mimics normal
liver
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/infantile-hemangioma_executive.pdf
January 01, 2016 - CT
Cohort studies: 1 (55)
Accuracy in detecting
liver IH
Insufficient Ultrasound detected lesions
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-203-adhd-disposition-comments.pdf
January 01, 2018 - 15: As for adverse events, the description should
include low blood pressure (alpha-2 agonists) and liver
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/restless-legs_executive.pdf
November 01, 2012 - patients with psychiatric or
other serious comorbid conditions, including patients
10
with renal or liver